Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Research & Development (2019 - 2025)

Avidity Biosciences' Research & Development history spans 7 years, with the latest figure at $166.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 74.22% year-over-year to $166.6 million; the TTM value through Dec 2025 reached $559.2 million, up 84.18%, while the annual FY2025 figure was $559.2 million, 84.18% up from the prior year.
  • Research & Development reached $166.6 million in Q4 2025 per RNA's latest filing, up from $154.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $166.6 million in Q4 2025 to a low of $20.7 million in Q1 2021.
  • Average Research & Development over 5 years is $65.3 million, with a median of $47.7 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 272.96% in 2021, then grew 7.25% in 2023.
  • A 5-year view of Research & Development shows it stood at $33.0 million in 2021, then soared by 38.35% to $45.6 million in 2022, then grew by 15.8% to $52.8 million in 2023, then surged by 81.05% to $95.6 million in 2024, then surged by 74.22% to $166.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Research & Development are $166.6 million (Q4 2025), $154.9 million (Q3 2025), and $138.1 million (Q2 2025).